細胞治療技術市場規模、シェア、動向、2030年までの世界予測

世界の細胞治療技術市場は、2025年の44億1,000万米ドルから2030年には79億1,000万米ドルに達すると予測されており、2025年から2030年にかけて年平均成長率（CAGR）は12.4%と大幅に伸びます。再生医療の進歩、慢性疾患の罹患率上昇、研究開発への投資増加、そしてCRISPRなどの遺伝子編集ツールの革新に牽引され、市場は力強い成長を遂げています。規制当局の支援と政府の資金提供に加え、バイオテクノロジー企業と学術機関の戦略的連携が、新たな細胞治療の開発を促進し、市場の成長を牽引しています。

調査範囲：

本調査レポートは、細胞治療技術市場を、製品（培地、血清、試薬、細胞工学製品、細胞培養容器、細胞治療機器、システムおよびソフトウェア、その他製品）、プロセス（細胞処理、細胞保存、細胞分配、細胞ハンドリング、プロセス監視および品質管理）、細胞の種類（T細胞、幹細胞、その他細胞）、用途（がん、心血管疾患（CVD）、整形外科疾患、自己免疫疾患、その他）、エンドユーザー（バイオ医薬品・バイオテクノロジー企業、CRO・CMO、研究機関、細胞バンク）、地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分類しています。本レポートは、市場の成長に影響を与える主要要因（促進要因、抑制要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの徹底的な分析により、各社の事業概要、製品、ソリューション、主要戦略、協業、パートナーシップ、契約に関する洞察を提供しています。細胞治療技術市場における最近の動向としては、新たな製品の発売、コラボレーション、買収などが挙げられます。

レポート購入の主なメリット：

本レポートは、細胞治療技術市場全体とそのサブセグメントの収益数値に最も近い概算値を提供することで、市場リーダー/新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、自社のポジショニングと適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。

本レポートは、以下の点について洞察を提供します。

市場の成長に影響を与える主要な推進要因（承認済みCGTの基盤拡大と臨床パイプラインの増加、CGT製造能力への資本投資の増加、同種異系およびiPSC由来プラットフォームのスケールアップ）、制約要因（高額な治療費と不確実な償還による商業量制限）、機会（自家移植治療のためのプラットフォーム化されたモジュール型製造ソリューション、AIやMLなどのデジタル技術との統合）、および課題（CGT製造および自動化における熟練労働力の不足）の分析。

• 製品開発／イノベーション：細胞治療技術市場における新製品に関する詳細な洞察。
• 市場開発：収益性の高い市場に関する包括的な情報。本レポートでは、様々な地域にわたる市場分析を提供しています。
• 市場の多様化：細胞治療技術市場における新製品、未開拓地域、最近の開発状況、投資に関する包括的な情報。
• 競合分析：ダナハー・コーポレーション（米国）、メルク（ドイツ）、サーモフィッシャーサイエンティフィック（米国）、ロンザ（スイス）、ザルトリウスAG（ドイツ）など。

Report Description

The global cell therapy technologies market is projected to reach USD 7.91 billion in 2030 from USD 4.41 billion in 2025, with a significant CAGR of 12.4% from 2025 to 2030. The market is experiencing strong growth, driven by advancements in regenerative medicine, the rising prevalence of chronic diseases, increasing investments in research and development, and innovations in gene editing tools, such as CRISPR. Regulatory support and government funding, along with strategic collaborations between biotech firms and academic institutions, are propelling the development of novel cell therapies, thereby driving market growth.

“The T-cells segment is projected to record the highest CAGR during the forecast period.”

The cell therapy technologies market is categorized into three primary categories based on cell type: T cells, stem cells, and other cell types. The T-cell segment is expected to grow at the fastest rate during the forecast period, driven by the strong clinical and commercial momentum of CAR-T and TCR therapies in cancer and their expansion into solid tumor indications. Furthermore, increasing regulatory approvals, favorable reimbursement decisions in significant markets, and growing physician familiarity with T-cell immunotherapies are encouraging broader adoption, which in turn boosts demand for specialized media, gene-editing tools, bioreactors, and analytics tailored to T-cell workflows within the cell therapy technology market.

“The cancer application segment accounted for the largest share in 2024.”

The application segment in the cell therapy technologies market includes cancer, cardiovascular disease (CVD), orthopaedic disorders, autoimmune diseases, and other applications. The cancer application segment dominated in 2024 due to the increasing prevalence of cancer globally and the rising demand for innovative, targeted therapies. Advancements in cell engineering, scalable manufacturing, and emerging applications in solid tumors further enhance the growth potential of this segment. It possesses a solid clinical pipeline, and government initiatives are highly supportive, with regulatory approvals facilitating the segment’s growth.

“The US dominated the North American cell therapy technologies market in 2024.”

The US is the largest biopharmaceutical market globally and a key hub for cell and gene therapy innovation, making it a core demand center for cell therapy technologies, products, and services. Demand is expected to rise further, supported by a sophisticated research ecosystem, strong venture and public funding, and the presence of foremost CGT technology leaders, including Thermo Fisher Scientific, Danaher, and Merck. The country benefits from substantial NIH and BARDA support for advanced therapies, as well as large precision medicine and population‑scale CGT initiatives run through leading academic and cancer centers. The high uptake of automated cell processing platforms, digital manufacturing, and advanced analytics across clinical and commercial facilities reinforces the US market’s leadership. In addition, a mature regulatory framework, robust healthcare infrastructure, and active public–private collaborations continue to foster rapid translation and commercialization of new cell therapy technologies in the US.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc.  (US), Avantor, Inc. (US),  Bio-Techne (US), Fresenius SE & Co KGAA (Germany), BD (US), Corning Incorporated (US), Terumo Corporation (Japan), GenScript (US), MaxCyte (US) and STEMCELL Technologies (Canada) are some of the major players operating in the cell therapy technologies market.

Research Coverage:

This research report categorizes the cell therapy technologies market by product (media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; systems & software; and other products), process (cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control), cell type (T-cells, stem cells, and other cells), application (cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications) end user (biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, and cell banks), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The report’s scope encompasses detailed information regarding the key factors, including drivers, restraints, challenges, and opportunities, that influence market growth. A thorough analysis of key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, and acquisitions are recent developments in the cell therapy technologies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (expanding base of approved CGTs and a growing clinical pipeline, growing capital investments in CGT manufacturing capacity, scale-up of allogeneic and iPSC-derived platforms) restraints (high therapy cost and uncertain reimbursement limiting commercial volumes), opportunities (platformized, modular manufacturing solutions for autologous therapies, integration with digital technologies such as AI & ML), and challenges (lack of skilled workforce in CGT manufacturing and automation) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell therapy technologies market.
• Competitive Assessment: Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), among others in the market.

Table of Contents

1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.3 STUDY SCOPE 40
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 41
1.3.2 INCLUSIONS & EXCLUSIONS 42
1.3.3 YEARS CONSIDERED 42
1.3.4 CURRENCY CONSIDERED 42
1.4 STAKEHOLDERS 43
1.5 SUMMARY OF CHANGES 43
2 EXECUTIVE SUMMARY 45
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 45
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS SHAPING MARKET 47
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 48
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49
3 PREMIUM INSIGHTS 50
3.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW 50
3.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY, 2024 51
3.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2025 VS. 2030 52
3.4 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
4 MARKET OVERVIEW 53
4.1 INTRODUCTION 53
4.2 MARKET DYNAMICS 53
4.2.1 DRIVERS 54
4.2.1.1 Expanding base of approved CGTs and growing clinical pipeline 54
4.2.1.2 Large capital investments in CGT manufacturing capacity 54
4.2.1.3 Growing shift towards closed and automated manufacturing 55
4.2.2 RESTRAINTS 55
4.2.2.1 Manufacturing and logistical complexity 55
4.2.2.2 High therapy cost and uncertain reimbursement limit commercial volumes 56
4.2.3 OPPORTUNITIES 56
4.2.3.1 Platformized and modular manufacturing solutions for autologous therapies 56
4.2.3.2 Development of personalized and off-the-shelf cell therapies 57
4.2.3.3 Integration with digital technologies 57
4.2.4 CHALLENGES 58
4.2.4.1 Lack of skilled workforce in CGT manufacturing and automation 58
4.3 UNMET NEEDS & WHITE SPACES 58
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 59
4.5 STRATEGIC MOVES BY TIER 1/2/3 COMPANIES 59
5 INDUSTRY TRENDS 60
5.1 PORTER’S FIVE FORCES ANALYSIS 60
5.1.1 THREAT OF NEW ENTRANTS 61
5.1.2 THREAT OF SUBSTITUTES 61
5.1.3 BARGAINING POWER OF BUYERS 61
5.1.4 BARGAINING POWER OF SUPPLIERS 61
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.2 MACROECONOMIC OUTLOOK 62
5.2.1 INTRODUCTION 62
5.2.2 GDP TRENDS AND FORECAST 62
5.2.3 TRENDS IN CELL THERAPY TECHNOLOGIES MARKET 63
5.2.4 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY 63
5.2.5 R&D TRENDS IN GLOBAL PHARMA INDUSTRY 63
5.3 ECOSYSTEM ANALYSIS 64
5.3.1 ROLE IN ECOSYSTEM 64
5.4 PRICING ANALYSIS 65
5.4.1 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022–2024 66
5.4.2 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2022–2024 67
5.5 VALUE CHAIN ANALYSIS 68
5.6 TRADE ANALYSIS 70
5.6.1 IMPORT SCENARIO FOR HS CODE 854330 70
5.6.2 IMPORT VOLUME FOR HS CODE 854330 71
5.6.3 EXPORT SCENARIO FOR HS CODE 854330, 2020–2024 71
5.6.4 EXPORT VOLUME FOR HS CODE 854330 72
5.7 KEY CONFERENCES AND EVENTS, 2026 73
5.8 INVESTMENT & FUNDING SCENARIO 73
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 75
5.10 IMPACT OF 2025 US TARIFF ON CELL THERAPY TECHNOLOGIES MARKET 76
5.10.1 KEY TARIFF RATES 76
5.10.2 PRICE IMPACT ANALYSIS 78
5.10.3 KEY IMPACT ON COUNTRIES/ REGION 78
5.10.3.1 US 78
5.10.3.2 Europe 79
5.10.3.3 Asia Pacific 79
5.10.4 END-USE INDUSTRY IMPACT 79
5.10.4.1 Biopharmaceutical and Biotechnology Companies 79
5.10.4.2 CROs and CMOs 80
5.10.4.3 Cell Banks 80
6 TECHNOLOGICAL ADVANCEMENTS, AI IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 81
6.1 TECHNOLOGY ANALYSIS 81
6.1.1 KEY EMERGING TECHNOLOGIES 81
6.1.1.1 Magnetic-activated cell sorting 81
6.1.1.2 Cryopreservation 81
6.1.1.3 Bioprocessing technologies 81
6.1.2 COMPLEMENTARY TECHNOLOGIES 82
6.1.2.1 Artificial intelligence and machine learning 82
6.1.2.2 Gene editing technologies 82
6.1.3 ADJACENT TECHNOLOGIES 82
6.1.3.1 Nanotechnology 82
6.1.3.2 Immunotherapy platforms 83
6.2 TECHNOLOGY/PRODUCT ROADMAP 83
6.3 PATENT ANALYSIS 83
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL THERAPY TECHNOLOGIES PATENTS, 2014–2024 84
6.4 FUTURE APPLICATIONS 86
6.5 IMPACT OF AI/GEN AI ON CELL THERAPY TECHNOLOGIES MARKET 86
6.5.1 TOP USE CASES AND MARKET POTENTIAL 87
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN CELL THERAPY TECHNOLOGIES MARKET 88
6.5.3 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN CELL THERAPY TECHNOLOGIES MARKET 88
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 90
7.1 REGULATORY LANDSCAPE 90
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
7.1.2 INDUSTRY STANDARDS 92
7.1.2.1 North America 93
7.1.2.2 Europe 93
7.1.2.3 Asia Pacific 93
7.1.2.4 Rest of the World 94
7.1.3 SUSTAINABILITY INITIATIVES, IMPACT, AND REGULATORY POLICY INITIATIVES 94
7.1.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 95
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 96
8.1 DECISION-MAKING PROCESS 96
8.2 KEY STAKEHOLDERS & BUYING CRITERIA 96
8.2.1 KEY STAKEHOLDERS 96
8.2.2 BUYING CRITERIA 97
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 99
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 100
9 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT 101
9.1 INTRODUCTION 102
9.2 MEDIA, SERA, AND REAGENTS 102
9.2.1 KEY IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET 102
9.3 CELL THERAPY EQUIPMENT 106
9.3.1 CELL PROCESSING EQUIPMENT 109
9.3.1.1 Development of automated and closed-system cell processing equipment to accelerate segment growth 109
9.3.2 SINGLE-USE EQUIPMENT 112
9.3.2.1 Increasing funding for stem cell therapy to propel market growth 112
9.3.3 OTHER CELL THERAPY EQUIPMENT 115
9.4 SYSTEMS & SOFTWARE 117
9.4.1 GROWING NEED FOR CELL THERAPIES TO AID SYSTEMS AND SOFTWARE ADOPTION 117
9.5 CELL CULTURE VESSELS 121
9.5.1 RISING R&D AND INVESTMENTS IN CELL-BASED THERAPIES TO AUGMENT MARKET DEMAND 121
9.6 CELL ENGINEERING PRODUCTS 123
9.6.1 AVAILABILITY OF WIDE RANGE OF CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH 123
9.7 OTHER PRODUCTS 127
10 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS 130
10.1 INTRODUCTION 131
10.2 CELL PROCESSING 131
10.2.1 CELL EXPANSION 134
10.2.1.1 Rising demand for personalized and regenerative therapies to drive market growth 134
10.2.2 CELL ISOLATION 137
10.2.2.1 Rising need for scalable and efficient isolation technologies to aid market growth 137
10.2.3 CELL CHARACTERIZATION 140
10.2.3.1 Increasing demand for high-quality, safe, and effective cell-based therapies to propel market growth 140

10.2.4 CELL COLLECTION 143
10.2.4.1 Advancements in cell collection technologies to propel market growth 143
10.3 CELL PRESERVATION 145
10.3.1 ADVANCEMENT IN CRYOPRESERVATION TECHNOLOGIES TO BOOST MARKET GROWTH 145
10.4 PROCESS MONITORING & QUALITY CONTROL 148
10.4.1 INCREASING DEMAND FOR AUTOMATED QUALITY CONTROL IN CELL THERAPY PRODUCTION TO FUEL MARKET GROWTH 148
10.5 CELL HANDLING 151
10.5.1 INCREASING DEMAND FOR AUTOMATED, EFFICIENT, AND SCALABLE SOLUTIONS TO ACCELERATE MARKET GROWTH 151
10.6 CELL DISTRIBUTION 154
10.6.1 INCREASED FOCUS ON TRANSPORTATION AND STORAGE TO DRIVE MARKET 154
11 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE 157
11.1 INTRODUCTION 158
11.2 T CELLS 158
11.2.1 GROWING RESEARCH ON CAR T-CELL THERAPY TO AID MARKET GROWTH 158
11.3 STEM CELLS 161
11.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO PROPEL MARKET GROWTH 161
11.4 OTHER CELLS 164
12 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION 167
12.1 INTRODUCTION 168
12.2 CANCER 168
12.2.1 FOCUS ON CAR T-CELL INNOVATION TO DRIVE SEGMENT EXPANSION 168
12.3 CARDIOVASCULAR DISEASES 171
12.3.1 INCREASING FOCUS ON INNOVATIVE CELL THERAPY APPROACHES TO DRIVE MARKET 171
12.4 ORTHOPEDIC DISORDERS 174
12.4.1 GROWING ADOPTION OF STEM CELL THERAPY FOR TISSUE REPAIR TO SUPPORT MARKET GROWTH 174
12.5 AUTOIMMUNE DISEASES 177
12.5.1 RISING INVESTMENTS IN STEM CELL RESEARCH TO FUEL MARKET GROWTH 177
12.6 OTHER APPLICATIONS 180
13 CELL THERAPY TECHNOLOGIES MARKET, BY END USER 184
13.1 INTRODUCTION 185
13.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 185
13.2.1 GROWING ADOPTION OF INORGANIC GROWTH STRATEGIES BY BIOPHARMACEUTICAL COMPANIES TO SUPPORT MARKET GROWTH 185

13.3 CROS & CMOS 189
13.3.1 GROWING FOCUS ON OUTSOURCING CLINICAL-SCALE PRECLINICAL & CLINICAL TRIALS TO DRIVE GROWTH 189
13.4 RESEARCH INSTITUTES 192
13.4.1 RISING FOCUS ON RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH 192
13.5 CELL BANKS 195
13.5.1 INCREASING DEMAND FOR STANDARDIZED CELL LINES TO SPUR MARKET GROWTH 195
14 CELL THERAPY TECHNOLOGIES MARKET, BY REGION 199
14.1 INTRODUCTION 200
14.2 NORTH AMERICA 200
14.2.1 US 204
14.2.1.1 US to dominate North American cell therapy technologies market during forecast period 204
14.2.2 CANADA 207
14.2.2.1 Favorable funding scenario to drive adoption of cell therapy instruments 207
14.3 EUROPE 210
14.3.1 GERMANY 213
14.3.1.1 Well-established pharmaceutical and R&D industry to aid Germany gain significant European market share 213
14.3.2 UK 216
14.3.2.1 Favorable funding and investment scenario to fuel market growth 216
14.3.3 FRANCE 220
14.3.3.1 Availability of government and private funding to fuel market growth 220
14.3.4 ITALY 223
14.3.4.1 Increased focus on public and private investment to offer growth opportunities 223
14.3.5 SPAIN 226
14.3.5.1 Advancement in personalized medicines to stimulate market growth 226
14.3.6 REST OF EUROPE 229
14.4 ASIA PACIFIC 232
14.4.1 CHINA 235
14.4.1.1 Focus on innovation and R&D in genetic research to drive market 235
14.4.2 JAPAN 238
14.4.2.1 Strong availability of funding for advanced cell therapies to aid market growth 238
14.4.3 INDIA 241
14.4.3.1 Substantial government R&D investments and focus of academic institutions on scientific innovation to drive market 241
14.4.4 SOUTH KOREA 244
14.4.4.1 Rising number of alliances and investments in research to boost market growth 244

14.4.5 AUSTRALIA 247
14.4.5.1 Increasing government funding and initiatives to drive market growth 247
14.4.6 REST OF ASIA PACIFIC 250
14.5 LATIN AMERICA 253
14.5.1 BRAZIL 257
14.5.1.1 Growing development of advanced therapies and robust pharmaceutical & biotechnology sectors to aid market growth 257
14.5.2 MEXICO 260
14.5.2.1 Growing pharmaceutical industry and rising government support to aid market growth 260
14.5.3 REST OF LATIN AMERICA 263
14.6 MIDDLE EAST 266
14.6.1 GCC COUNTRIES 268
14.6.1.1 Kingdom of Saudi Arabia 271
14.6.1.1.1 Increasing government investments in healthcare to support market growth 271
14.6.1.2 UAE 275
14.6.1.2.1 Growing R&D expenditure and well-established class infrastructure to spur market growth 275
14.6.1.3 Rest of GCC Countries 278
14.6.2 REST OF MIDDLE EAST 281
14.7 AFRICA 283
14.7.1 INCREASING HEALTH AND RESEARCH SPENDING TO PROPEL MARKET DEMAND FOR ADVANCED CELL THERAPY TECHNOLOGIES 283
15 COMPETITIVE LANDSCAPE 287
15.1 INTRODUCTION 287
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 287
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET 287
15.3 REVENUE ANALYSIS, 2022–2024 288
15.4 MARKET SHARE ANALYSIS, 2024 289
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 291
15.5.1 STARS 291
15.5.2 EMERGING LEADERS 291
15.5.3 PERVASIVE PLAYERS 292
15.5.4 PARTICIPANTS 292
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 293
15.5.5.1 Company footprint 293
15.5.5.2 Region footprint 293
15.5.5.3 Product footprint 294
15.5.5.4 Cell type footprint 295
15.5.5.5 Application footprint 296

15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 297
15.6.1 PROGRESSIVE COMPANIES 297
15.6.2 RESPONSIVE COMPANIES 297
15.6.3 DYNAMIC COMPANIES 297
15.6.4 STARTING BLOCKS 297
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 298
15.6.5.1 Detailed list of key startups/SMEs 298
15.6.5.2 Competitive benchmarking of startups/SMEs 299
15.7 COMPANY VALUATION & FINANCIAL METRICS 300
15.7.1 FINANCIAL METRICS 300
15.7.2 COMPANY VALUATION 300
15.8 BRAND/PRODUCT COMPARISON 301
15.9 COMPETITIVE SCENARIO 301
15.9.1 PRODUCT LAUNCHES 301
15.9.2 DEALS 302
15.9.3 EXPANSIONS 303
16 COMPANY PROFILES 304
16.1 KEY PLAYERS 304
16.1.1 DANAHER CORPORATION 304
16.1.1.1 Business overview 304
16.1.1.2 Products offered 305
16.1.1.3 Recent developments 310
16.1.1.3.1 Product launches 310
16.1.1.3.2 Deals 310
16.1.1.3.3 Expansions 311
16.1.1.4 MnM view 312
16.1.1.4.1 Key strengths 312
16.1.1.4.2 Strategic choices 312
16.1.1.4.3 Weaknesses & competitive threats 312
16.1.2 MERCK KGAA 313
16.1.2.1 Business overview 313
16.1.2.2 Products offered 314
16.1.2.3 Recent developments 316
16.1.2.3.1 Deals 316
16.1.2.3.2 Expansions 317
16.1.2.4 MnM view 317
16.1.2.4.1 Key strengths 317
16.1.2.4.2 Strategic choices 317
16.1.2.4.3 Weaknesses & competitive threats 317

16.1.3 THERMO FISHER SCIENTIFIC INC. 318
16.1.3.1 Business overview 318
16.1.3.2 Products offered 319
16.1.3.3 Recent developments 330
16.1.3.3.1 Product launches 330
16.1.3.3.2 Deals 331
16.1.3.3.3 Expansions 331
16.1.3.4 MnM view 332
16.1.3.4.1 Key strengths 332
16.1.3.4.2 Strategic choices 332
16.1.3.4.3 Weaknesses & competitive threats 332
16.1.4 LONZA 333
16.1.4.1 Business overview 333
16.1.4.2 Products offered 334
16.1.4.3 Recent developments 338
16.1.4.3.1 Product launches 338
16.1.4.3.2 Deals 339
16.1.4.3.3 Expansions 339
16.1.4.4 MnM view 339
16.1.4.4.1 Key strengths 339
16.1.4.4.2 Strategic choices 340
16.1.4.4.3 Weaknesses & competitive threats 340
16.1.5 SARTORIUS AG 341
16.1.5.1 Business overview 341
16.1.5.2 Products offered 342
16.1.5.3 Recent developments 346
16.1.5.3.1 Deals 346
16.1.5.3.2 Expansions 346
16.1.5.4 MnM view 347
16.1.5.4.1 Key strengths 347
16.1.5.4.2 Strategic choices 347
16.1.5.4.3 Weaknesses & competitive threats 347
16.1.6 AGILENT TECHNOLOGIES, INC. 348
16.1.6.1 Business overview 348
16.1.6.2 Products offered 349
16.1.6.3 Recent developments 350
16.1.6.3.1 Product launches 350
16.1.6.3.2 Deals 351
16.1.6.4 MnM view 351
16.1.6.4.1 Key strengths 351
16.1.6.4.2 Strategic choices 351
16.1.6.4.3 Weaknesses & competitive threats 351
16.1.7 AVANTOR, INC. 352
16.1.7.1 Business overview 352
16.1.7.2 Products offered 353
16.1.7.3 Recent developments 359
16.1.7.3.1 Product launches 359
16.1.7.3.2 Deals 359
16.1.8 FRESENIUS SE & CO. KGAA 360
16.1.8.1 Business overview 360
16.1.8.2 Products offered 361
16.1.8.3 Recent developments 362
16.1.8.3.1 Deals 362
16.1.9 BECTON, DICKINSON AND COMPANY (BD) 363
16.1.9.1 Business overview 363
16.1.9.2 Products offered 364
16.1.9.3 Recent developments 366
16.1.9.3.1 Product launches 366
16.1.9.3.2 Deals 366
16.1.10 CORNING INCORPORATED 367
16.1.10.1 Business overview 367
16.1.10.2 Products offered 368
16.1.11 TERUMO CORPORATION 372
16.1.11.1 Business overview 372
16.1.11.2 Products offered 373
16.1.11.3 Recent developments 374
16.1.11.3.1 Product launches 374
16.1.11.3.2 Deals 374
16.1.11.3.3 Expansions 375
16.1.12 BIO-TECHNE 376
16.1.12.1 Business overview 376
16.1.12.2 Products offered 377
16.1.12.3 Recent developments 383
16.1.12.3.1 Product launches 383
16.1.12.3.2 Deals 383
16.1.12.3.3 Other developments 383
16.1.13 GENSCRIPT 384
16.1.13.1 Business overview 384
16.1.13.2 Products offered 385
16.1.13.3 Recent developments 387
16.1.13.3.1 Deals 387
16.1.13.3.2 Other developments 388

16.1.14 MAXCYTE 389
16.1.14.1 Business overview 389
16.1.14.2 Products offered 390
16.1.14.3 Recent developments 392
16.1.14.3.1 Deals 392
16.1.15 STEMCELL TECHNOLOGIES 394
16.1.15.1 Business overview 394
16.1.15.2 Products offered 394
16.1.15.3 Recent developments 400
16.1.15.3.1 Product launches 400
16.1.15.3.2 Deals 400
16.2 OTHER PLAYERS 401
16.2.1 ROOSTERBIO, INC. 401
16.2.2 MILTENYI BIOTEC 402
16.2.3 TRAKCEL 403
16.2.4 L7 INFORMATICS, INC. 404
16.2.5 REPLIGEN CORPORATION 405
16.2.6 MAK SYSTEM 406
16.2.7 ORIGEN BIOMEDICAL, INC. 407
16.2.8 IXCELLS BIOTECHNOLOGIES 408
16.2.9 KÖRBER AG 410
16.2.10 KRISHGEN BIOSYSTEMS 411
17 RESEARCH METHODOLOGY 412
17.1 RESEARCH DATA 412
17.1.1 SECONDARY DATA 412
17.1.1.1 Key objectives of secondary research 413
17.1.2 PRIMARY DATA 413
17.1.2.1 Breakdown of primaries 414
17.1.2.2 Objectives of primary research 414
17.2 MARKET ESTIMATION METHODOLOGY 415
17.2.1 MARKET ESTIMATION 415
17.2.2 INSIGHTS FROM PRIMARY EXPERTS 417
17.2.3 TOP-DOWN APPROACH 418
17.3 MARKET GROWTH RATE PROJECTIONS 419
17.4 DATA TRIANGULATION 421
17.5 STUDY ASSUMPTIONS 421
17.6 RESEARCH LIMITATIONS 422
17.7 RISK ANALYSIS 423

18 APPENDIX 424
18.1 DISCUSSION GUIDE 424
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 428
18.3 CUSTOMIZATION OPTIONS 430
18.4 RELATED REPORTS 430
18.5 AUTHOR DETAILS 431

LIST OF TABLES

TABLE 1 CELL THERAPY TECHNOLOGIES MARKET: INCLUSIONS & EXCLUSIONS 42
TABLE 2 IMPACT OF PORTER’S FIVE FORCES ON CELL THERAPY TECHNOLOGIES MARKET 61
TABLE 3 ROLE OF COMPANIES IN ECOSYSTEM IN CELL THERAPY TECHNOLOGIES MARKET 64
TABLE 4 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 66
TABLE 5 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY REGION, 2022–2024 (USD) 67
TABLE 6 IMPORT VALUE FOR HS CODE 854330, 2020–2024 (USD THOUSAND) 70
TABLE 7 IMPORT VOLUME FOR HS CODE 854330, 2020–2024 (UNITS) 71
TABLE 8 EXPORT VALUE FOR HS CODE 854330, 2020–2024 (USD THOUSAND) 71
TABLE 9 EXPORT VOLUME FOR HS CODE 854330, 2020–2024 (UNITS) 72
TABLE 10 KEY CONFERENCES & EVENTS IN CELL THERAPY TECHNOLOGIES MARKET, JANUARY 2026–DECEMBER 2026 73
TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES 76
TABLE 12 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO CELL THERAPY TECHNOLOGIES MARKET 78
TABLE 13 CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS, 2025 84
TABLE 14 CASE STUDIES OF AI IMPLEMENTATION IN CELL THERAPY TECHNOLOGIES MARKET 88
TABLE 15 CLIENT’S READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN CELL THERAPY TECHNOLOGIES MARKET 88
TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 19 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 20 VENDOR CERTIFICATIONS IN CELL THERAPY TECHNOLOGIES MARKET 95
TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS 97
TABLE 22 KEY BUYING CRITERIA FOR CELL THERAPY TECHNOLOGIES PRODUCTS,
BY END USER 98
TABLE 23 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 102
TABLE 24 CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION,
2023–2030 (USD MILLION) 103
TABLE 25 NORTH AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 26 EUROPE: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 27 ASIA PACIFIC: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 28 LATIN AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 29 MIDDLE EAST: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 105
TABLE 30 GCC COUNTRIES: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 31 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 106
TABLE 32 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 107
TABLE 33 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 107
TABLE 34 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 107
TABLE 35 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 108
TABLE 36 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 108
TABLE 37 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY REGION,
2023–2030 (USD MILLION) 108
TABLE 38 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 109
TABLE 39 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 40 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 41 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 42 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 43 LATIN AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 44 MIDDLE EAST: CELL PROCESSING EQUIPMENT MARKET, BY REGION,
2023–2030 (USD MILLION) 111
TABLE 45 GCC COUNTRIES: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 46 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 112
TABLE 47 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 113
TABLE 48 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 113
TABLE 49 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 113
TABLE 50 LATIN AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 51 MIDDLE EAST: SINGLE-USE EQUIPMENT MARKET, BY REGION,
2023–2030 (USD MILLION) 114
TABLE 52 GCC COUNTRIES: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 53 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION,
2023–2030 (USD MILLION) 115
TABLE 54 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 55 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 116
TABLE 56 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 116
TABLE 57 LATIN AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 58 MIDDLE EAST: OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION,
2023–2030 (USD MILLION) 117
TABLE 59 GCC COUNTRIES: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 60 MAJOR CELL THERAPY SYSTEMS & SOFTWARE, BY COMPANY 118
TABLE 61 CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION,
2023–2030 (USD MILLION) 118
TABLE 62 NORTH AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 63 EUROPE: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 119
TABLE 64 ASIA PACIFIC: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 65 LATIN AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 66 MIDDLE EAST: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 120
TABLE 67 GCC COUNTRIES: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 68 CELL CULTURE VESSELS MARKET, BY REGION, 2023–2030 (USD MILLION) 121
TABLE 69 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 121
TABLE 70 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 122
TABLE 71 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 122
TABLE 72 LATIN AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 122
TABLE 73 MIDDLE EAST: CELL CULTURE VESSELS MARKET, BY REGION,
2023–2030 (USD MILLION) 123
TABLE 74 GCC COUNTRIES: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 123
TABLE 75 CELL ENGINEERING PRODUCTS OFFERED BY KEY COMPANIES 124
TABLE 76 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 124
TABLE 77 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 125
TABLE 78 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 125
TABLE 79 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 125
TABLE 80 LATIN AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 126
TABLE 81 MIDDLE EAST: CELL ENGINEERING PRODUCTS MARKET, BY REGION,
2023–2030 (USD MILLION) 126
TABLE 82 GCC COUNTRIES: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 126
TABLE 83 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION,
2023–2030 (USD MILLION) 127
TABLE 84 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 85 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 128
TABLE 86 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 128
TABLE 87 LATIN AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 128
TABLE 88 MIDDLE EAST: OTHER CELL THERAPY PRODUCTS MARKET, BY REGION,
2023–2030 (USD MILLION) 129
TABLE 89 GCC COUNTRIES: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 90 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 131
TABLE 91 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE,
2023–2030 (USD MILLION) 132
TABLE 92 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2023–2030 (USD MILLION) 132
TABLE 93 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 94 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 95 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 96 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 97 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2023–2030 (USD MILLION) 134
TABLE 98 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 99 CELL EXPANSION MARKET, BY REGION, 2023–2030 (USD MILLION) 135
TABLE 100 NORTH AMERICA: CELL EXPANSION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 135
TABLE 101 EUROPE: CELL EXPANSION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 102 ASIA PACIFIC: CELL EXPANSION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 136
TABLE 103 LATIN AMERICA: CELL EXPANSION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 136
TABLE 104 MIDDLE EAST: CELL EXPANSION MARKET, BY REGION, 2023–2030 (USD MILLION) 136
TABLE 105 GCC COUNTRIES: CELL EXPANSION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 137
TABLE 106 CELL ISOLATION MARKET, BY REGION, 2023–2030 (USD MILLION) 138
TABLE 107 NORTH AMERICA: CELL ISOLATION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 138
TABLE 108 EUROPE: CELL ISOLATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 109 ASIA PACIFIC: CELL ISOLATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 110 LATIN AMERICA: CELL ISOLATION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 139
TABLE 111 MIDDLE EAST: CELL ISOLATION MARKET, BY REGION, 2023–2030 (USD MILLION) 139
TABLE 112 GCC COUNTRIES: CELL ISOLATION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 140
TABLE 113 CELL CHARACTERIZATION MARKET, BY REGION, 2023–2030 (USD MILLION) 140
TABLE 114 NORTH AMERICA: CELL CHARACTERIZATION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 141
TABLE 115 EUROPE: CELL CHARACTERIZATION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 141
TABLE 116 ASIA PACIFIC: CELL CHARACTERIZATION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 141
TABLE 117 LATIN AMERICA: CELL CHARACTERIZATION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 142
TABLE 118 MIDDLE EAST: CELL CHARACTERIZATION MARKET, BY REGION,
2023–2030 (USD MILLION) 142
TABLE 119 GCC COUNTRIES: CELL CHARACTERIZATION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 142
TABLE 120 CELL COLLECTION MARKET, BY REGION, 2023–2030 (USD MILLION) 143
TABLE 121 NORTH AMERICA: CELL COLLECTION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 144
TABLE 122 EUROPE: CELL COLLECTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 123 ASIA PACIFIC: CELL COLLECTION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 144
TABLE 124 LATIN AMERICA: CELL COLLECTION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 145
TABLE 125 MIDDLE EAST: CELL COLLECTION MARKET, BY REGION,
2023–2030 (USD MILLION) 145
TABLE 126 GCC COUNTRIES: CELL COLLECTION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 145
TABLE 127 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2023–2030 (USD MILLION) 146
TABLE 128 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 129 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION,
BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 130 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 131 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 132 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2023–2030 (USD MILLION) 148
TABLE 133 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 134 PROCESS MONITORING & QUALITY CONTROL MARKET, BY REGION,
2023–2030 (USD MILLION) 149
TABLE 135 NORTH AMERICA: PROCESS MONITORING & QUALITY CONTROL MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 136 EUROPE: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 137 ASIA PACIFIC: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 138 LATIN AMERICA: PROCESS MONITORING & QUALITY CONTROL MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 139 MIDDLE EAST: PROCESS MONITORING & QUALITY CONTROL MARKET, BY REGION, 2023–2030 (USD MILLION) 151
TABLE 140 GCC COUNTRIES: PROCESS MONITORING & QUALITY CONTROL MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 141 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY REGION, 2023–2030 (USD MILLION) 152
TABLE 142 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 143 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING,
BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 144 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING,
BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 145 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 146 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING,
BY REGION, 2023–2030 (USD MILLION) 153
TABLE 147 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 148 CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2023–2030 (USD MILLION) 154
TABLE 149 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 150 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION,
BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 151 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 152 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 153 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2023–2030 (USD MILLION) 156
TABLE 154 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 155 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 158
TABLE 156 T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 159
TABLE 157 NORTH AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 158 EUROPE: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 159
TABLE 159 ASIA PACIFIC: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 160
TABLE 160 LATIN AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 160
TABLE 161 MIDDLE EAST: T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 160
TABLE 162 GCC COUNTRIES: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 161
TABLE 163 STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 162
TABLE 164 NORTH AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 165 EUROPE: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 162
TABLE 166 ASIA PACIFIC: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 167 LATIN AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 168 MIDDLE EAST: STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 163
TABLE 169 GCC COUNTRIES: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 170 OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 164
TABLE 171 NORTH AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 172 EUROPE: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 165
TABLE 173 ASIA PACIFIC: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 174 LATIN AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 175 MIDDLE EAST: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 166
TABLE 176 GCC COUNTRIES: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 177 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 168
TABLE 178 CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION,
2023–2030 (USD MILLION) 169
TABLE 179 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 180 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 181 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 182 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 183 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION) 171
TABLE 184 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 185 CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES,
BY REGION, 2023–2030 (USD MILLION) 172
TABLE 186 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 187 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 188 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 189 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 190 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 174
TABLE 191 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 192 CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS,
BY REGION, 2023–2030 (USD MILLION) 175
TABLE 193 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 194 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 195 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 196 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 197 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 177
TABLE 198 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 199 CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES,
BY REGION, 2023–2030 (USD MILLION) 178
TABLE 200 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 201 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 202 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 203 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 204 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION) 180
TABLE 205 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 206 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 181
TABLE 207 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 208 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 209 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 210 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 211 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 182
TABLE 212 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 213 CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 185
TABLE 214 CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 186
TABLE 215 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 187
TABLE 216 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 217 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 218 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 188
TABLE 219 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 188
TABLE 220 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 188
TABLE 221 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION,
2023–2030 (USD MILLION) 190
TABLE 222 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 223 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 224 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 225 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 226 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY REGION, 2023–2030 (USD MILLION) 191
TABLE 227 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 228 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 193
TABLE 229 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 230 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES,
BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 231 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 232 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 233 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 194
TABLE 234 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 195
TABLE 235 CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY REGION,
2023–2030 (USD MILLION) 196
TABLE 236 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 237 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 238 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 239 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 240 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY REGION, 2023–2030 (USD MILLION) 197
TABLE 241 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 242 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 200
TABLE 243 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 201
TABLE 244 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 202
TABLE 245 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 202
TABLE 246 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 202
TABLE 247 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 203
TABLE 248 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 203
TABLE 249 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 203
TABLE 250 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 204
TABLE 251 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 205
TABLE 252 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 253 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 205
TABLE 254 US: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 206
TABLE 255 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 206
TABLE 256 US: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 206
TABLE 257 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 207
TABLE 258 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 208
TABLE 259 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 208
TABLE 260 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 208
TABLE 261 CANADA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING
BY TYPE, 2023–2030 (USD MILLION) 209
TABLE 262 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 209
TABLE 263 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 209
TABLE 264 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 210
TABLE 265 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 211
TABLE 266 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 211
TABLE 267 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 211
TABLE 268 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023–2030 (USD MILLION) 212
TABLE 269 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 212
TABLE 270 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 212
TABLE 271 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 213
TABLE 272 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 214
TABLE 273 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 214
TABLE 274 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 215
TABLE 275 GERMANY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023–2030 (USD MILLION) 215
TABLE 276 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 215
TABLE 277 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 216
TABLE 278 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 216
TABLE 279 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 217
TABLE 280 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 218
TABLE 281 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 218
TABLE 282 UK: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 218
TABLE 283 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 219
TABLE 284 UK: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 219
TABLE 285 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 219
TABLE 286 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 220
TABLE 287 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 221
TABLE 288 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 221
TABLE 289 FRANCE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023–2030 (USD MILLION) 221
TABLE 290 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 222
TABLE 291 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 222
TABLE 292 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 222
TABLE 293 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 223
TABLE 294 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 224
TABLE 295 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 224
TABLE 296 ITALY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 224
TABLE 297 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 225
TABLE 298 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 225
TABLE 299 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 225
TABLE 300 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 226
TABLE 301 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 227
TABLE 302 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 227
TABLE 303 SPAIN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 227
TABLE 304 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 228
TABLE 305 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 228
TABLE 306 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 228
TABLE 307 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 229
TABLE 308 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 230
TABLE 309 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 230
TABLE 310 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 230
TABLE 311 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 231
TABLE 312 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 231
TABLE 313 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 231
TABLE 314 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 233
TABLE 315 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 233
TABLE 316 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 233
TABLE 317 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023–2030 (USD MILLION) 234
TABLE 318 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 234
TABLE 319 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 234
TABLE 320 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 235
TABLE 321 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 236
TABLE 322 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 236
TABLE 323 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 236
TABLE 324 CHINA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 237
TABLE 325 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 237
TABLE 326 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 237
TABLE 327 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 238
TABLE 328 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 239
TABLE 329 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 239
TABLE 330 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 240
TABLE 331 JAPAN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 240
TABLE 332 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 240
TABLE 333 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 241
TABLE 334 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 241
TABLE 335 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 242
TABLE 336 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 242
TABLE 337 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 243
TABLE 338 INDIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 243
TABLE 339 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 243
TABLE 340 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 244
TABLE 341 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 244
TABLE 342 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 245
TABLE 343 SOUTH KOREA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 245
TABLE 344 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 246
TABLE 345 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 246
TABLE 346 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 246
TABLE 347 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 247
TABLE 348 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 247
TABLE 349 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 248
TABLE 350 AUSTRALIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 248
TABLE 351 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 249
TABLE 352 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023–2030 (USD MILLION) 249
TABLE 353 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 249
TABLE 354 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 250
TABLE 355 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 250
TABLE 356 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 251
TABLE 357 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 251
TABLE 358 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 252
TABLE 359 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 252
TABLE 360 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 252
TABLE 361 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 253
TABLE 362 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 253
TABLE 363 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 254
TABLE 364 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 254
TABLE 365 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 255
TABLE 366 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 255
TABLE 367 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 255
TABLE 368 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 256
TABLE 369 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 256
TABLE 370 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 256
TABLE 371 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 257
TABLE 372 BRAZIL: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 258
TABLE 373 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 258
TABLE 374 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023–2030 (USD MILLION) 258
TABLE 375 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 259
TABLE 376 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 259
TABLE 377 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 259
TABLE 378 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 260
TABLE 379 MEXICO: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 261
TABLE 380 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 261
TABLE 381 MEXICO: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023–2030 (USD MILLION) 261
TABLE 382 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 262
TABLE 383 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 262
TABLE 384 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 262
TABLE 385 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 263
TABLE 386 REST OF LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 264
TABLE 387 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 264
TABLE 388 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 264
TABLE 389 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 265
TABLE 390 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 265
TABLE 391 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 265
TABLE 392 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 266
TABLE 393 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 266
TABLE 394 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 267
TABLE 395 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 267
TABLE 396 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 267
TABLE 397 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 268
TABLE 398 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 268
TABLE 399 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 269
TABLE 400 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 269
TABLE 401 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 269
TABLE 402 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 270
TABLE 403 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 270
TABLE 404 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 270
TABLE 405 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 271
TABLE 406 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 271
TABLE 407 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 272
TABLE 408 KINGDOM OF SAUDI ARABIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 273
TABLE 409 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET,
BY PROCESS, 2023–2030 (USD MILLION) 273
TABLE 410 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 273
TABLE 411 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 274
TABLE 412 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 274
TABLE 413 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 274
TABLE 414 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 275
TABLE 415 UAE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 276
TABLE 416 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 276
TABLE 417 UAE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 276
TABLE 418 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 277
TABLE 419 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 277
TABLE 420 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 277
TABLE 421 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 278
TABLE 422 REST OF GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 279
TABLE 423 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 279
TABLE 424 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 279
TABLE 425 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 280
TABLE 426 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 280
TABLE 427 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 280
TABLE 428 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 281
TABLE 429 REST OF MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 281
TABLE 430 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 282
TABLE 431 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023–2030 (USD MILLION) 282
TABLE 432 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023–2030 (USD MILLION) 282
TABLE 433 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 283
TABLE 434 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 283
TABLE 435 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 284
TABLE 436 AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2023–2030 (USD MILLION) 284
TABLE 437 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 285
TABLE 438 AFRICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2023–2030 (USD MILLION) 285
TABLE 439 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2023–2030 (USD MILLION) 285
TABLE 440 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 286
TABLE 441 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 286
TABLE 442 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2022–2024 287
TABLE 443 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION 290
TABLE 444 CELL THERAPY TECHNOLOGIES MARKET: REGION FOOTPRINT 293
TABLE 445 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT 294
TABLE 446 CELL THERAPY TECHNOLOGIES MARKET: CELL TYPE FOOTPRINT 295
TABLE 447 CELL THERAPY TECHNOLOGIES MARKET: APPLICATION FOOTPRINT 296
TABLE 448 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 298
TABLE 449 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY PRODUCT AND REGION 299
TABLE 450 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES,
JANUARY 2022–DECEMBER 2025 301
TABLE 451 CELL THERAPY TECHNOLOGIES MARKET: DEALS,
JANUARY 2022–DECEMBER 2025 302
TABLE 452 CELL THERAPY TECHNOLOGIES MARKET: EXPANSIONS,
JANUARY 2022–DECEMBER 2025 303
TABLE 453 DANAHER CORPORATION: COMPANY OVERVIEW 304
TABLE 454 DANAHER CORPORATION: PRODUCTS OFFERED 305
TABLE 455 DANAHER CORPORATION: PRODUCT LAUNCHES,
JANUARY 2022–DECEMBER 2025 310
TABLE 456 DANAHER CORPORATION: DEALS, JANUARY 2022–DECEMBER 2025 310
TABLE 457 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022–DECEMBER 2025 311
TABLE 458 MERCK KGAA: COMPANY OVERVIEW 313
TABLE 459 MERCK KGAA: PRODUCTS OFFERED 314
TABLE 460 MERCK KGAA: DEALS, JANUARY 2022–DECEMBER 2025 316
TABLE 461 MERCK KGAA: EXPANSIONS, JANUARY 2022–DECEMBER 2025 317
TABLE 462 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 318
TABLE 463 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 319
TABLE 464 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES,
JANUARY 2022–DECEMBER 2025 330
TABLE 465 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–DECEMBER 2025 331
TABLE 466 THERMO FISHER SCIENTIFIC INC: EXPANSIONS, JANUARY 2021–OCTOBER 2024 331
TABLE 467 LONZA: COMPANY OVERVIEW 333
TABLE 468 LONZA: PRODUCTS OFFERED 334
TABLE 469 LONZA: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 338
TABLE 470 LONZA: DEALS, JANUARY 2022–DECEMBER 2025 339
TABLE 471 LONZA: EXPANSIONS, JANUARY 2022–DECEMBER 2025 339
TABLE 472 SARTORIUS AG: COMPANY OVERVIEW 341
TABLE 473 SARTORIUS AG: PRODUCTS OFFERED 342
TABLE 474 SARTORIUS AG: DEALS, JANUARY 2022–DECEMBER 2025 346
TABLE 475 SARTORIUS AG: EXPANSIONS, JANUARY 2022–DECEMBER 2025 346
TABLE 476 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 348
TABLE 477 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 349
TABLE 478 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES,
JANUARY 2022–DECEMBER 2025 350
TABLE 479 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022– DECEMBER 2025 351
TABLE 480 AVANTOR, INC.: COMPANY OVERVIEW 352
TABLE 481 AVANTOR, INC.: PRODUCTS OFFERED 353
TABLE 482 AVANTOR, INC.: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 359
TABLE 483 AVANTOR, INC.: DEALS, JANUARY 2022–DECEMBER 2025 359
TABLE 484 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW 360
TABLE 485 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED 361
TABLE 486 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2022–DECEMBER 2025 362
TABLE 487 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 363
TABLE 488 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 364
TABLE 489 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES,
JANUARY 2022–DECEMBER 2025 366
TABLE 490 BECTON, DICKINSON AND COMPANY (BD): DEALS,
JANUARY 2022–DECEMBER 2025 366
TABLE 491 CORNING INCORPORATED: COMPANY OVERVIEW 367
TABLE 492 CORNING INCORPORATED: PRODUCTS OFFERED 368
TABLE 493 TERUMO CORPORATION: COMPANY OVERVIEW 372
TABLE 494 TERUMO CORPORATION: PRODUCTS OFFERED 373
TABLE 495 TERUMO CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 374
TABLE 496 TERUMO CORPORATION: DEALS, JANUARY 2022–DECEMBER 2025 374
TABLE 497 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–DECEMBER 2025 375
TABLE 498 BIO-TECHNE: COMPANY OVERVIEW 376
TABLE 499 BIO-TECHNE: PRODUCTS OFFERED 377
TABLE 500 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 383
TABLE 501 BIO-TECHNE: DEALS, JANUARY 2022–DECEMBER 2025 383
TABLE 502 BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 383
TABLE 503 GENSCRIPT: COMPANY OVERVIEW 384
TABLE 504 GENSCRIPT: PRODUCTS OFFERED 385
TABLE 505 GENSCRIPT: DEALS, JANUARY 2022–DECEMBER 2025 387
TABLE 506 GENSCRIPT: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 388
TABLE 507 MAXCYTE: COMPANY OVERVIEW 389
TABLE 508 MAXCYTE: PRODUCTS OFFERED 390
TABLE 509 MAXCYTE: DEALS, JANUARY 2022–DECEMBER 2024 392
TABLE 510 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW 394
TABLE 511 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED 394
TABLE 512 STEMCELL TECHNOLOGIES: PRODUCT LAUNCHES,
JANUARY 2022–DECEMBER 2025 400
TABLE 513 STEMCELL TECHNOLOGIES: DEALS, JANUARY 2022–DECEMBER 2025 400
TABLE 514 ROOSTERBIO, INC.: COMPANY OVERVIEW 401
TABLE 515 MILTENYI BIOTEC: COMPANY OVERVIEW 402
TABLE 516 TRAKCEL: COMPANY OVERVIEW 403
TABLE 517 L7 INFORMATICS, INC.: COMPANY OVERVIEW 404
TABLE 518 REPLIGEN CORPORATION: COMPANY OVERVIEW 405
TABLE 519 MAK SYSTEM: COMPANY OVERVIEW 406
TABLE 520 ORIGEN BIOMEDICAL, INC.: COMPANY OVERVIEW 407
TABLE 521 IXCELLS BIOTECHNOLOGIES: COMPANY OVERVIEW 408
TABLE 522 KÖRBER AG: COMPANY OVERVIEW 410
TABLE 523 KRISHGEN BIOSYSTEMS: COMPANY OVERVIEW 411
TABLE 524 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 420
TABLE 525 CELL THERAPY TECHNOLOGIES MARKET: RISK ANALYSIS 423

LIST OF FIGURES

FIGURE 1 CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION & REGIONAL SCOPE 41
FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: YEARS CONSIDERED 42
FIGURE 3 MARKET SCENARIO OF CELL THERAPY TECHNOLOGIES MARKET 45
FIGURE 4 GLOBAL CELL THERAPY TECHNOLOGIES MARKET, 2023–2030 (USD MILLION) 46
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2020–2025 46
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF CELL THERAPY TECHNOLOGIES MARKET 47
FIGURE 7 HIGH-GROWTH SEGMENTS IN CELL THERAPY TECHNOLOGIES MARKET,
2025–2030 48
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CELL THERAPY TECHNOLOGIES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 49
FIGURE 9 INCREASED FUNDING & INVESTMENT IN CELL THERAPY AND GROWING PRODUCT PIPELINE TO DRIVE MARKET 50
FIGURE 10 US AND T-CELLS DOMINATED LARGEST NORTH AMERCIAN MARKET SHARE
IN 2024 51
FIGURE 11 MEDIA, SERA, AND REAGENTS TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD 52
FIGURE 12 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 52
FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 60
FIGURE 15 GROWTH OF GLOBAL GDP FROM 2020 TO 2024, WITH FORECAST UNTIL 2030 62
FIGURE 16 CELL THERAPY TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS 64
FIGURE 17 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2024 (USD) 68
FIGURE 18 VALUE CHAIN ANALYSIS IN CELL THERAPY TECHNOLOGIES MARKET 69
FIGURE 19 GOVERNMENT FUNDING FOR R&D, 2019–2024 75
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS IN CELL THERAPY TECHNOLOGIES MARKET 75
FIGURE 21 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL THERAPY TECHNOLOGIES PATENTS, 2014–2024 84
FIGURE 22 IMPACT OF AI IN CELL THERAPY TECHNOLOGIES MARKET 87
FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 97
FIGURE 24 KEY BUYING CRITERIA FOR END USERS 98
FIGURE 25 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 201
FIGURE 26 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 232
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2022–2024 (USD MILLION) 289
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET (2024) 290
FIGURE 29 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 292
FIGURE 30 CELL THERAPY TECHNOLOGIES MARKET: COMPANY FOOTPRINT 293
FIGURE 31 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 298
FIGURE 32 EV/EBITDA OF KEY VENDORS 300
FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 300
FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 301
FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT 305
FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT 314
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 319
FIGURE 38 LONZA: COMPANY SNAPSHOT 334
FIGURE 39 SARTORIUS AG: COMPANY SNAPSHOT 342
FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 349
FIGURE 41 AVANTOR, INC.: COMPANY SNAPSHOT 353
FIGURE 42 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT 361
FIGURE 43 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT 364
FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT 368
FIGURE 45 TERUMO CORPORATION: COMPANY SNAPSHOT 373
FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT 377
FIGURE 47 GENSCRIPT: COMPANY SNAPSHOT 385
FIGURE 48 MAXCYTE: COMPANY SNAPSHOT 390
FIGURE 49 CELL THERAPY TECHNOLOGIES MARKET: RESEARCH DESIGN 412
FIGURE 50 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 414
FIGURE 51 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2024 415
FIGURE 52 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024 416
FIGURE 53 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION: REVENUE SHARE ANALYSIS (2024) 416
FIGURE 54 CELL THERAPY TECHNOLOGIES MARKET SIZE VALIDATION FROM PRIMARY SOURCES 417
FIGURE 55 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 418
FIGURE 56 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS 419
FIGURE 57 CELL THERAPY TECHNOLOGIES MARKET: DATA TRIANGULATION METHODOLOGY 421

---

---